-
Published on Jul 28, 2016
Hybridan’s
Niall Pearson tells biotech investors that drug trial failure is ‘the
nature of the beast’ and speaking with Proactive Investors he
highlighted examples where selling has gone too far.
“When companies have them [trial failures] there’s a big hooha and everyone forgets what they are actually investing in,” Pearson said.
The broker notes Circassia - which recently plummeted more than 60% as a cat allergy treatment trial disappointed - as an example where the market showed a knee-jerk reaction.
Pearson also talked about the ‘long game’ of regaining trust, the importance of diversification, and the opportunities for investing in companies developing drugs for rare diseases and conditions where there are unmet medical needs.
One such example identified by Pearson is Amryt Pharma Plc (LONLAMYT) - a (sort-of) recent addition to the market that will certainly be familiar to avid followers of Proactive Investors.
“When companies have them [trial failures] there’s a big hooha and everyone forgets what they are actually investing in,” Pearson said.
The broker notes Circassia - which recently plummeted more than 60% as a cat allergy treatment trial disappointed - as an example where the market showed a knee-jerk reaction.
Pearson also talked about the ‘long game’ of regaining trust, the importance of diversification, and the opportunities for investing in companies developing drugs for rare diseases and conditions where there are unmet medical needs.
One such example identified by Pearson is Amryt Pharma Plc (LONLAMYT) - a (sort-of) recent addition to the market that will certainly be familiar to avid followers of Proactive Investors.
No comments:
Post a Comment